LivaNova Bulls Lift Targets After Q3 Print

LivaNova heads into the post-earnings stretch with short sellers sitting on an elevated position, analysts upgrading their conviction, and a retail attention spike that stands out against the quiet backdrop of recent months.

The clearest move this week came from the Street. Needham's Mike Matson raised his price target to $112 from $93 today, keeping his Buy rating, after the company reported Q3 results this morning. That follows Barclays initiating coverage at Overweight with a $105 target just four weeks ago. The direction of analyst travel is firmly bullish: every coverage change over the past four months has been an upgrade or a target lift, with the sole exception of a Hold initiation from Freedom Capital Markets in July. The mean analyst target now looks stale at $90.55 in the ORTEX data, but the two most recent actions point well above $100, suggesting that figure will reset materially upward in coming days. The stock closed at $79.90, so even the more conservative targets imply meaningful upside from here.

Short positioning is the tension in the story. At 11.4% of free float, the bears have a real stake. That figure has climbed roughly 14% over the past month, from around 5.5 million shares shorted in late September to just over 6.2 million now, a meaningful build. Yet the lending market is not particularly stressed. Availability is running at 472% of short interest, comfortably above its 52-week low of 423%, meaning there is ample room for new shorts to establish positions without squeezing existing borrowers. Borrowing costs are low at 0.49%, up 32% on the week but still well below any level that would signal a forced unwind. Options confirm the lack of urgency: the put/call ratio is 0.48, essentially in line with its 20-day average and closer to the 52-week call-heavy extreme than the put-heavy one. Shorts are present but not panicking, and options traders are not hedging aggressively.

The bull case rests on a pipeline and a revenue ramp. Management has guided 2025 revenue to $940 million to $955 million, against $803 million in 2024, a jump that depends on both the cardiopulmonary and neuromodulation divisions delivering. The more speculative element is the aura6000 device, where bulls model $120 million of revenue in 2027 rising to $280 million by 2029 under a favourable FDA outcome. Bears counter that neuromodulation growth is already slowing and that operating margins are under pressure, with the aura6000 approval timeline adding binary risk to those projections. Valuation sits at a P/E of 17.3 and EV/EBITDA of 11.5, both having edged lower over the past 30 days. The ORTEX factor scores flag a strong EPS surprise rank of 87th percentile and an analyst recommendation differential in the 94th percentile, the latter reflecting how much more bullish the analysts covering the stock are compared to the broader universe. Short score and days-to-cover both rank in the bottom 10th percentile, flagging the elevated short position as a genuine differentiator.

One piece of colour worth noting: retail attention spiked sharply around the earnings date, with the ORTEX Wikipedia/page-view signal hitting a z-score of 5.8 as of October 19. That kind of attention spike typically accompanies a catalyst. With results now out, it will be worth watching whether the retail interest persists or fades.

Insider activity over the past 90 days leans net negative, with roughly $800,000 more sold than bought on an open-market basis, led by two directors selling small clips in September. None of the sales were under 10b5-1 plans, though the amounts involved are small relative to the institutional register. BlackRock holds 13.7% and added over 400,000 shares in the quarter to September, the largest absolute addition among the top holders. FMR (Fidelity) also added nearly 500,000 shares in the period, a meaningful vote of confidence from two of the stock's largest institutional backers.

The next scheduled earnings date is February 24, 2027. Between now and then, the central question is whether today's Q3 beat and the analyst target upgrades are enough to begin closing the gap between the $79.90 price and the growing cluster of targets above $100, or whether the still-elevated short interest reflects a view that the aura6000 approval path contains more risk than the bulls are pricing in.